Wednesday, May 14, 2008

HemCon Acquires Ireland-Based Alltracel Pharma

HemCon Medical Technologies announced Wednesday that it has concluded its cash-for-stock acquisition of Alltracel Pharmaceuticals Plc. Terms of the deal were not disclosed. HemCon said it made the purchase through its newly formed and wholly owned subsidiary, Castlerise Investments Ltd. Headquartered in Dublin, Ireland, Alltracel licenses its technologies across the cosmeceutical, nutraceutical and wound-care markets. The company also offers oral care products in Europe through the Butler and GUM brands. HemCon said Alltracel will remain in Dublin, adding that it expects combined revenues to exceed $100 million. Founded in 2001, HemCon Medical Technologies develops and manufactures medical devices to control bleeding and infection resulting from trauma or surgery.